EA022588B1 - Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце - Google Patents

Info

Publication number

EA022588B1

EA022588B1 EA201001488A EA201001488A EA022588B1 EA 022588 B1 EA022588 B1 EA 022588B1 EA 201001488 A EA201001488 A EA 201001488A EA 201001488 A EA201001488 A EA 201001488A EA 022588 B1 EA022588 B1 EA 022588B1

Authority

EA

Eurasian Patent Office

Prior art keywords

compound

disease

mmol

inflammatory

compounds

Prior art date

2008-04-18

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003963 antioxidant agent Substances 0.000 title abstract description 18
• 230000003078 antioxidant effect Effects 0.000 title abstract description 18
• MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title abstract description 12
• 230000004054 inflammatory process Effects 0.000 title description 80
• 206010061218 Inflammation Diseases 0.000 title description 66
• 150000001875 compounds Chemical class 0.000 claims abstract description 277
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 115
• 201000010099 disease Diseases 0.000 claims abstract description 100
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
• 238000011282 treatment Methods 0.000 claims description 55
• -1 hydroxy, amino, dimethylamino, methyl Chemical group 0.000 claims description 44
• 239000003814 drug Substances 0.000 claims description 37
• 229940079593 drug Drugs 0.000 claims description 34
• 230000002757 inflammatory effect Effects 0.000 claims description 32
• 125000003118 aryl group Chemical group 0.000 claims description 31
• 206010028980 Neoplasm Diseases 0.000 claims description 30
• 125000004429 atom Chemical group 0.000 claims description 29
• 206010012601 diabetes mellitus Diseases 0.000 claims description 28
• 150000003839 salts Chemical class 0.000 claims description 28
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 26
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 25
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 25
• 230000006378 damage Effects 0.000 claims description 25
• 201000011510 cancer Diseases 0.000 claims description 24
• 201000004681 Psoriasis Diseases 0.000 claims description 22
• 208000011231 Crohn disease Diseases 0.000 claims description 21
• 230000003287 optical effect Effects 0.000 claims description 21
• 125000000217 alkyl group Chemical group 0.000 claims description 20
• 125000001072 heteroaryl group Chemical group 0.000 claims description 19
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 18
• 230000001684 chronic effect Effects 0.000 claims description 18
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 15
• 125000006413 ring segment Chemical group 0.000 claims description 15
• 125000003342 alkenyl group Chemical group 0.000 claims description 14
• 229910052739 hydrogen Inorganic materials 0.000 claims description 14
• 239000001257 hydrogen Substances 0.000 claims description 14
• 206010025135 lupus erythematosus Diseases 0.000 claims description 14
• 208000023275 Autoimmune disease Diseases 0.000 claims description 13
• 125000003282 alkyl amino group Chemical group 0.000 claims description 12
• 125000003545 alkoxy group Chemical group 0.000 claims description 11
• 230000004770 neurodegeneration Effects 0.000 claims description 11
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
• 201000001320 Atherosclerosis Diseases 0.000 claims description 10
• 125000000304 alkynyl group Chemical group 0.000 claims description 10
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 9
• 125000004475 heteroaralkyl group Chemical group 0.000 claims description 9
• 208000011580 syndromic disease Diseases 0.000 claims description 9
• 206010063837 Reperfusion injury Diseases 0.000 claims description 8
• 208000006011 Stroke Diseases 0.000 claims description 8
• 125000000033 alkoxyamino group Chemical group 0.000 claims description 8
• 208000017520 skin disease Diseases 0.000 claims description 8
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
• 230000001154 acute effect Effects 0.000 claims description 7
• 125000003368 amide group Chemical group 0.000 claims description 7
• 125000001769 aryl amino group Chemical group 0.000 claims description 7
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
• 230000002265 prevention Effects 0.000 claims description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
• 206010020772 Hypertension Diseases 0.000 claims description 6
• 206010022489 Insulin Resistance Diseases 0.000 claims description 6
• 125000004423 acyloxy group Chemical group 0.000 claims description 6
• 125000006323 alkenyl amino group Chemical group 0.000 claims description 6
• 125000003302 alkenyloxy group Chemical group 0.000 claims description 6
• 125000006319 alkynyl amino group Chemical group 0.000 claims description 6
• 125000005133 alkynyloxy group Chemical group 0.000 claims description 6
• 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 6
• 125000004104 aryloxy group Chemical group 0.000 claims description 6
• 125000005241 heteroarylamino group Chemical group 0.000 claims description 6
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
• 125000005843 halogen group Chemical group 0.000 claims description 5
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 5
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 5
• 208000017169 kidney disease Diseases 0.000 claims description 5
• 231100000331 toxic Toxicity 0.000 claims description 5
• 230000002588 toxic effect Effects 0.000 claims description 5
• 208000008589 Obesity Diseases 0.000 claims description 4
• 239000004480 active ingredient Substances 0.000 claims description 4
• 235000020824 obesity Nutrition 0.000 claims description 4
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
• 208000017442 Retinal disease Diseases 0.000 claims description 3
• 206010038923 Retinopathy Diseases 0.000 claims description 3
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 125000001153 fluoro group Chemical group F* 0.000 claims description 3
• 230000000302 ischemic effect Effects 0.000 claims description 3
• 201000001119 neuropathy Diseases 0.000 claims description 3
• 230000007823 neuropathy Effects 0.000 claims description 3
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
• 206010048554 Endothelial dysfunction Diseases 0.000 claims description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
• 206010000496 acne Diseases 0.000 claims description 2
• 208000037849 arterial hypertension Diseases 0.000 claims description 2
• 201000008937 atopic dermatitis Diseases 0.000 claims description 2
• 208000029078 coronary artery disease Diseases 0.000 claims description 2
• 230000008694 endothelial dysfunction Effects 0.000 claims description 2
• 208000010706 fatty liver disease Diseases 0.000 claims description 2
• 229910052731 fluorine Inorganic materials 0.000 claims description 2
• 230000003902 lesion Effects 0.000 claims description 2
• 206010028320 muscle necrosis Diseases 0.000 claims description 2
• 239000012217 radiopharmaceutical Substances 0.000 claims description 2
• 229940121896 radiopharmaceutical Drugs 0.000 claims description 2
• 230000002799 radiopharmaceutical effect Effects 0.000 claims description 2
• 230000002485 urinary effect Effects 0.000 claims description 2
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 229940044683 chemotherapy drug Drugs 0.000 claims 1
• 239000011737 fluorine Substances 0.000 claims 1
• 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
• 239000000243 solution Substances 0.000 description 95
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 95
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 83
• 239000000203 mixture Substances 0.000 description 73
• 238000000034 method Methods 0.000 description 66
• 239000000126 substance Substances 0.000 description 56
• 238000006243 chemical reaction Methods 0.000 description 53
• 210000004027 cell Anatomy 0.000 description 51
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 50
• 210000001519 tissue Anatomy 0.000 description 49
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 48
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 48
• 239000011541 reaction mixture Substances 0.000 description 42
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
• 239000000741 silica gel Substances 0.000 description 38
• 229910002027 silica gel Inorganic materials 0.000 description 38
• 230000000694 effects Effects 0.000 description 37
• 238000004519 manufacturing process Methods 0.000 description 37
• 239000000284 extract Substances 0.000 description 36
• 238000004440 column chromatography Methods 0.000 description 35
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
• 102000010907 Cyclooxygenase 2 Human genes 0.000 description 29
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 29
• 238000001914 filtration Methods 0.000 description 29
• 230000015572 biosynthetic process Effects 0.000 description 28
• 102000004127 Cytokines Human genes 0.000 description 27
• 108090000695 Cytokines Proteins 0.000 description 27
• 230000037396 body weight Effects 0.000 description 27
• 230000006698 induction Effects 0.000 description 27
• 230000036542 oxidative stress Effects 0.000 description 27
• 239000000047 product Substances 0.000 description 27
• 238000003756 stirring Methods 0.000 description 26
• 239000003153 chemical reaction reagent Substances 0.000 description 25
• 239000012043 crude product Substances 0.000 description 25
• 238000011161 development Methods 0.000 description 25
• 230000018109 developmental process Effects 0.000 description 25
• 230000001225 therapeutic effect Effects 0.000 description 25
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 24
• 239000002904 solvent Substances 0.000 description 24
• 238000001816 cooling Methods 0.000 description 23
• 208000024891 symptom Diseases 0.000 description 23
• 206010003246 arthritis Diseases 0.000 description 22
• 210000003169 central nervous system Anatomy 0.000 description 22
• 230000005764 inhibitory process Effects 0.000 description 22
• 229910052799 carbon Inorganic materials 0.000 description 21
• 210000004072 lung Anatomy 0.000 description 20
• 238000003786 synthesis reaction Methods 0.000 description 20
• 241000282414 Homo sapiens Species 0.000 description 19
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
• 230000004913 activation Effects 0.000 description 19
• 238000001035 drying Methods 0.000 description 19
• 239000003607 modifier Substances 0.000 description 19
• 230000001988 toxicity Effects 0.000 description 19
• 231100000419 toxicity Toxicity 0.000 description 19
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
• 125000004432 carbon atom Chemical group C* 0.000 description 18
• 210000001503 joint Anatomy 0.000 description 18
• 108090000623 proteins and genes Proteins 0.000 description 18
• 241000700159 Rattus Species 0.000 description 17
• 210000004369 blood Anatomy 0.000 description 17
• 239000008280 blood Substances 0.000 description 17
• 239000012267 brine Substances 0.000 description 17
• 230000007170 pathology Effects 0.000 description 17
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 16
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 16
• 210000001072 colon Anatomy 0.000 description 16
• 208000002551 irritable bowel syndrome Diseases 0.000 description 16
• 230000036470 plasma concentration Effects 0.000 description 16
• 235000006708 antioxidants Nutrition 0.000 description 15
• 208000035475 disorder Diseases 0.000 description 15
• 230000000670 limiting effect Effects 0.000 description 15
• 239000000523 sample Substances 0.000 description 15
• 208000001647 Renal Insufficiency Diseases 0.000 description 14
• 201000006370 kidney failure Diseases 0.000 description 14
• 229910052757 nitrogen Inorganic materials 0.000 description 14
• 239000002253 acid Substances 0.000 description 13
• VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 13
• 210000002540 macrophage Anatomy 0.000 description 13
• 239000002244 precipitate Substances 0.000 description 13
• 241000283984 Rodentia Species 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 12
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
• 229910052760 oxygen Inorganic materials 0.000 description 12
• 230000000770 proinflammatory effect Effects 0.000 description 12
• 239000000725 suspension Substances 0.000 description 12
• 208000002193 Pain Diseases 0.000 description 11
• 230000001965 increasing effect Effects 0.000 description 11
• 208000015181 infectious disease Diseases 0.000 description 11
• 208000028867 ischemia Diseases 0.000 description 11
• 210000003734 kidney Anatomy 0.000 description 11
• 210000000056 organ Anatomy 0.000 description 11
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 11
• 102000004169 proteins and genes Human genes 0.000 description 11
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 10
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 241000699670 Mus sp. Species 0.000 description 10
• 125000002252 acyl group Chemical group 0.000 description 10
• 210000004556 brain Anatomy 0.000 description 10
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 10
• 125000004122 cyclic group Chemical group 0.000 description 10
• 230000002354 daily effect Effects 0.000 description 10
• 239000008103 glucose Substances 0.000 description 10
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
• 229910052700 potassium Inorganic materials 0.000 description 10
• 235000018102 proteins Nutrition 0.000 description 10
• 210000003491 skin Anatomy 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
• 208000006045 Spondylarthropathies Diseases 0.000 description 9
• 210000001744 T-lymphocyte Anatomy 0.000 description 9
• 125000002015 acyclic group Chemical group 0.000 description 9
• 230000014509 gene expression Effects 0.000 description 9
• 201000001441 melanoma Diseases 0.000 description 9
• 201000006417 multiple sclerosis Diseases 0.000 description 9
• 239000012074 organic phase Substances 0.000 description 9
• 101150072179 ATP1 gene Proteins 0.000 description 8
• 101100003366 Arabidopsis thaliana ATPA gene Proteins 0.000 description 8
• 206010003267 Arthritis reactive Diseases 0.000 description 8
• 102100021649 Elongator complex protein 6 Human genes 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 101100065219 Homo sapiens ELP6 gene Proteins 0.000 description 8
• 102000008070 Interferon-gamma Human genes 0.000 description 8
• 108010074328 Interferon-gamma Proteins 0.000 description 8
• 108060001084 Luciferase Proteins 0.000 description 8
• 241000282567 Macaca fascicularis Species 0.000 description 8
• 101150105046 atpI gene Proteins 0.000 description 8
• 150000001721 carbon Chemical group 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 150000002085 enols Chemical class 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 210000000987 immune system Anatomy 0.000 description 8
• 239000003112 inhibitor Substances 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 150000002576 ketones Chemical class 0.000 description 8
• 150000003180 prostaglandins Chemical class 0.000 description 8
• 208000002574 reactive arthritis Diseases 0.000 description 8
• 238000003753 real-time PCR Methods 0.000 description 8
• 210000002966 serum Anatomy 0.000 description 8
• 235000011803 sesame oil Nutrition 0.000 description 8
• 239000008159 sesame oil Substances 0.000 description 8
• 208000024827 Alzheimer disease Diseases 0.000 description 7
• 206010003253 Arthritis enteropathic Diseases 0.000 description 7
• 239000005089 Luciferase Substances 0.000 description 7
• 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 7
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 7
• 108091023040 Transcription factor Proteins 0.000 description 7
• 102000040945 Transcription factor Human genes 0.000 description 7
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
• UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
• 230000017531 blood circulation Effects 0.000 description 7
• 208000020832 chronic kidney disease Diseases 0.000 description 7
• 229940126214 compound 3 Drugs 0.000 description 7
• 210000001280 germinal center Anatomy 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 230000004968 inflammatory condition Effects 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 239000001301 oxygen Substances 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 238000010898 silica gel chromatography Methods 0.000 description 7
• 239000011734 sodium Substances 0.000 description 7
• 201000005671 spondyloarthropathy Diseases 0.000 description 7
• 125000000547 substituted alkyl group Chemical group 0.000 description 7
• 230000009885 systemic effect Effects 0.000 description 7
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• 102000000546 Apoferritins Human genes 0.000 description 6
• 108010002084 Apoferritins Proteins 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
• 208000003456 Juvenile Arthritis Diseases 0.000 description 6
• 210000000988 bone and bone Anatomy 0.000 description 6
• 238000011088 calibration curve Methods 0.000 description 6
• 239000013256 coordination polymer Substances 0.000 description 6
• 229940109239 creatinine Drugs 0.000 description 6
• 230000008482 dysregulation Effects 0.000 description 6
• 238000001704 evaporation Methods 0.000 description 6
• 230000008020 evaporation Effects 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 239000006260 foam Substances 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
• 210000000274 microglia Anatomy 0.000 description 6
• 210000000653 nervous system Anatomy 0.000 description 6
• 125000004433 nitrogen atom Chemical group N* 0.000 description 6
• 230000002093 peripheral effect Effects 0.000 description 6
• 230000004936 stimulating effect Effects 0.000 description 6
• 230000001629 suppression Effects 0.000 description 6
• UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 5
• 206010003805 Autism Diseases 0.000 description 5
• 208000020706 Autistic disease Diseases 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 5
• 206010012735 Diarrhoea Diseases 0.000 description 5
• 102100033398 Glutamate-cysteine ligase regulatory subunit Human genes 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 208000032843 Hemorrhage Diseases 0.000 description 5
• 102000004877 Insulin Human genes 0.000 description 5
• 108090001061 Insulin Proteins 0.000 description 5
• 208000012659 Joint disease Diseases 0.000 description 5
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 5
• 208000018737 Parkinson disease Diseases 0.000 description 5
• 206010037660 Pyrexia Diseases 0.000 description 5
• 206010040047 Sepsis Diseases 0.000 description 5
• 201000002661 Spondylitis Diseases 0.000 description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
• 206010043255 Tendonitis Diseases 0.000 description 5
• 208000007536 Thrombosis Diseases 0.000 description 5
• 208000025865 Ulcer Diseases 0.000 description 5
• 230000006907 apoptotic process Effects 0.000 description 5
• 210000001367 artery Anatomy 0.000 description 5
• 230000001363 autoimmune Effects 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 230000034994 death Effects 0.000 description 5
• 231100000517 death Toxicity 0.000 description 5
• 239000006185 dispersion Substances 0.000 description 5
• 208000020947 enthesitis Diseases 0.000 description 5
• 210000001508 eye Anatomy 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 150000002431 hydrogen Chemical class 0.000 description 5
• 201000001421 hyperglycemia Diseases 0.000 description 5
• 238000003119 immunoblot Methods 0.000 description 5
• 230000001771 impaired effect Effects 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 229940125396 insulin Drugs 0.000 description 5
• 229960003130 interferon gamma Drugs 0.000 description 5
• 230000000968 intestinal effect Effects 0.000 description 5
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 5
• 231100000053 low toxicity Toxicity 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 230000008506 pathogenesis Effects 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 230000003244 pro-oxidative effect Effects 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000002035 prolonged effect Effects 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 210000000813 small intestine Anatomy 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 229910052717 sulfur Inorganic materials 0.000 description 5
• 239000011593 sulfur Substances 0.000 description 5
• 201000004595 synovitis Diseases 0.000 description 5
• 230000009897 systematic effect Effects 0.000 description 5
• 230000000451 tissue damage Effects 0.000 description 5
• 231100000827 tissue damage Toxicity 0.000 description 5
• 231100000397 ulcer Toxicity 0.000 description 5
• 208000016261 weight loss Diseases 0.000 description 5
• 230000004580 weight loss Effects 0.000 description 5
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
• FKHUGQZRBPETJR-RXSRXONKSA-N (2r)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 4
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 4
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 4
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
• 208000004998 Abdominal Pain Diseases 0.000 description 4
• 102000007469 Actins Human genes 0.000 description 4
• 108010085238 Actins Proteins 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• 208000000094 Chronic Pain Diseases 0.000 description 4
• 101150065749 Churc1 gene Proteins 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• 206010016654 Fibrosis Diseases 0.000 description 4
• 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 4
• 102000015696 Interleukins Human genes 0.000 description 4
• 108010063738 Interleukins Proteins 0.000 description 4
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 4
• 102100038239 Protein Churchill Human genes 0.000 description 4
• 102100037580 Sesquipedalian-1 Human genes 0.000 description 4
• 101710169844 Sesquipedalian-1 Proteins 0.000 description 4
• 102000001639 Thioredoxin Reductase 1 Human genes 0.000 description 4
• 108010093836 Thioredoxin Reductase 1 Proteins 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 208000038016 acute inflammation Diseases 0.000 description 4
• 230000006022 acute inflammation Effects 0.000 description 4
• 208000007502 anemia Diseases 0.000 description 4
• 229940124599 anti-inflammatory drug Drugs 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 4
• KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 208000034158 bleeding Diseases 0.000 description 4
• 230000000740 bleeding effect Effects 0.000 description 4
• 239000007853 buffer solution Substances 0.000 description 4
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 208000019069 chronic childhood arthritis Diseases 0.000 description 4
• 229940125904 compound 1 Drugs 0.000 description 4
• 229940125797 compound 12 Drugs 0.000 description 4
• 229940125833 compound 23 Drugs 0.000 description 4
• 229940125961 compound 24 Drugs 0.000 description 4
• 229940125877 compound 31 Drugs 0.000 description 4
• 229940125898 compound 5 Drugs 0.000 description 4
• 206010015037 epilepsy Diseases 0.000 description 4
• 230000003628 erosive effect Effects 0.000 description 4
• 125000003709 fluoroalkyl group Chemical group 0.000 description 4
• 235000013305 food Nutrition 0.000 description 4
• 230000037406 food intake Effects 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 4
• 230000028709 inflammatory response Effects 0.000 description 4
• 208000028774 intestinal disease Diseases 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 230000033001 locomotion Effects 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 208000010125 myocardial infarction Diseases 0.000 description 4
• 230000003959 neuroinflammation Effects 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 150000002978 peroxides Chemical class 0.000 description 4
• CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 4
• 210000000664 rectum Anatomy 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 229950003733 romurtide Drugs 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
• 235000017557 sodium bicarbonate Nutrition 0.000 description 4
• 238000004885 tandem mass spectrometry Methods 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 231100000041 toxicology testing Toxicity 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
• IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
• STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
• ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
• NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 3
• QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
• 208000036487 Arthropathies Diseases 0.000 description 3
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
• 208000008035 Back Pain Diseases 0.000 description 3
• 208000020925 Bipolar disease Diseases 0.000 description 3
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 102000019034 Chemokines Human genes 0.000 description 3
• 108010012236 Chemokines Proteins 0.000 description 3
• 208000035473 Communicable disease Diseases 0.000 description 3
• 229940126657 Compound 17 Drugs 0.000 description 3
• 229940126639 Compound 33 Drugs 0.000 description 3
• BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical group O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 206010018364 Glomerulonephritis Diseases 0.000 description 3
• 206010019280 Heart failures Diseases 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 241000282553 Macaca Species 0.000 description 3
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
• 208000001132 Osteoporosis Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108010039491 Ricin Proteins 0.000 description 3
• PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 3
• 208000021386 Sjogren Syndrome Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
• SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 229910052788 barium Inorganic materials 0.000 description 3
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000008499 blood brain barrier function Effects 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 210000001218 blood-brain barrier Anatomy 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000003833 cell viability Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 229960002173 citrulline Drugs 0.000 description 3
• 239000004927 clay Substances 0.000 description 3
• 229940126543 compound 14 Drugs 0.000 description 3
• 229940126142 compound 16 Drugs 0.000 description 3
• 229940125782 compound 2 Drugs 0.000 description 3
• 229940126086 compound 21 Drugs 0.000 description 3
• 229940126208 compound 22 Drugs 0.000 description 3
• 229940125846 compound 25 Drugs 0.000 description 3
• 229940127204 compound 29 Drugs 0.000 description 3
• 229940125878 compound 36 Drugs 0.000 description 3
• 229940125807 compound 37 Drugs 0.000 description 3
• 229940127573 compound 38 Drugs 0.000 description 3
• 230000008602 contraction Effects 0.000 description 3
• 230000002596 correlated effect Effects 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 229960001334 corticosteroids Drugs 0.000 description 3
• 230000001186 cumulative effect Effects 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 239000004744 fabric Substances 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 229940044627 gamma-interferon Drugs 0.000 description 3
• 239000010437 gem Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 230000001788 irregular Effects 0.000 description 3
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 3
• 230000003907 kidney function Effects 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 230000000116 mitigating effect Effects 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 125000004430 oxygen atom Chemical group O* 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 239000003642 reactive oxygen metabolite Substances 0.000 description 3
• 239000002464 receptor antagonist Substances 0.000 description 3
• 229940044551 receptor antagonist Drugs 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 230000000392 somatic effect Effects 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 125000005017 substituted alkenyl group Chemical group 0.000 description 3
• 125000005415 substituted alkoxy group Chemical group 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 210000001179 synovial fluid Anatomy 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 150000003648 triterpenes Chemical class 0.000 description 3
• ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
• UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
• ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
• UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 2
• YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
• TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
• APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
• AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 208000008822 Ankylosis Diseases 0.000 description 2
• 102000004452 Arginase Human genes 0.000 description 2
• 108700024123 Arginases Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 101100428016 Caenorhabditis elegans upp-1 gene Proteins 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 229940127007 Compound 39 Drugs 0.000 description 2
• 206010010774 Constipation Diseases 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
• 208000010201 Exanthema Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 208000010412 Glaucoma Diseases 0.000 description 2
• 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 2
• 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 208000013016 Hypoglycemia Diseases 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 102000003777 Interleukin-1 beta Human genes 0.000 description 2
• 108090000193 Interleukin-1 beta Proteins 0.000 description 2
• 206010022941 Iridocyclitis Diseases 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• 208000032382 Ischaemic stroke Diseases 0.000 description 2
• 206010023198 Joint ankylosis Diseases 0.000 description 2
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
• 108090001030 Lipoproteins Proteins 0.000 description 2
• 102000004895 Lipoproteins Human genes 0.000 description 2
• 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
• 206010028116 Mucosal inflammation Diseases 0.000 description 2
• 201000010927 Mucositis Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 102000015336 Nerve Growth Factor Human genes 0.000 description 2
• GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
• YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
• MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
• 206010033645 Pancreatitis Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 102000034527 Retinoid X Receptors Human genes 0.000 description 2
• 108010038912 Retinoid X Receptors Proteins 0.000 description 2
• 208000025747 Rheumatic disease Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
• 239000012346 acetyl chloride Substances 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• 230000003044 adaptive effect Effects 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 238000002399 angioplasty Methods 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 201000004612 anterior uveitis Diseases 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 210000000436 anus Anatomy 0.000 description 2
• 239000012062 aqueous buffer Substances 0.000 description 2
• 210000001130 astrocyte Anatomy 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• 230000031018 biological processes and functions Effects 0.000 description 2
• 239000007844 bleaching agent Substances 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• 238000009534 blood test Methods 0.000 description 2
• 210000001715 carotid artery Anatomy 0.000 description 2
• 229960000590 celecoxib Drugs 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
• 235000013477 citrulline Nutrition 0.000 description 2
• 230000001149 cognitive effect Effects 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 229940125810 compound 20 Drugs 0.000 description 2
• 229940125851 compound 27 Drugs 0.000 description 2
• 239000002872 contrast media Substances 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 230000001120 cytoprotective effect Effects 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 230000002996 emotional effect Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000005713 exacerbation Effects 0.000 description 2
• 201000005884 exanthem Diseases 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 210000003608 fece Anatomy 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 230000000762 glandular Effects 0.000 description 2
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 231100000086 high toxicity Toxicity 0.000 description 2
• 235000012907 honey Nutrition 0.000 description 2
• 230000002218 hypoglycaemic effect Effects 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 125000001841 imino group Chemical group [H]N=* 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000008798 inflammatory stress Effects 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
• 210000003127 knee Anatomy 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 230000001926 lymphatic effect Effects 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 210000000214 mouth Anatomy 0.000 description 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
• SDWXTQCFTPNNKU-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-n',n'-bis[2-(pyridin-2-ylmethylamino)ethyl]ethane-1,2-diamine Chemical compound C=1C=CC=NC=1CNCCN(CCNCC=1N=CC=CC=1)CCNCC1=CC=CC=N1 SDWXTQCFTPNNKU-UHFFFAOYSA-N 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 229940100243 oleanolic acid Drugs 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
• 230000004792 oxidative damage Effects 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 208000012102 polyarticular juvenile rheumatoid arthritis Diseases 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 238000004393 prognosis Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 239000012264 purified product Substances 0.000 description 2
• 238000012797 qualification Methods 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 206010037844 rash Diseases 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 210000003131 sacroiliac joint Anatomy 0.000 description 2
• 235000002020 sage Nutrition 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 210000003079 salivary gland Anatomy 0.000 description 2
• 201000000980 schizophrenia Diseases 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 230000035807 sensation Effects 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• 210000004927 skin cell Anatomy 0.000 description 2
• 231100000046 skin rash Toxicity 0.000 description 2
• 230000001954 sterilising effect Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 125000004426 substituted alkynyl group Chemical group 0.000 description 2
• 125000003107 substituted aryl group Chemical group 0.000 description 2
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 210000001258 synovial membrane Anatomy 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000002834 transmittance Methods 0.000 description 2
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 210000000689 upper leg Anatomy 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 230000025033 vasoconstriction Effects 0.000 description 2
• 230000004584 weight gain Effects 0.000 description 2
• 235000019786 weight gain Nutrition 0.000 description 2
• ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
• SEULWJSKCVACTH-UHFFFAOYSA-N 1-phenylimidazole Chemical group C1=NC=CN1C1=CC=CC=C1 SEULWJSKCVACTH-UHFFFAOYSA-N 0.000 description 1
• VDNAQZFBFKLYFA-UHFFFAOYSA-N 2,2-dioxo-1,3,2-dioxathiolan-4-ol Chemical compound OC1COS(=O)(=O)O1 VDNAQZFBFKLYFA-UHFFFAOYSA-N 0.000 description 1
• ICQNCHSXWNQIHC-UHFFFAOYSA-N 2-oxopropanedial Chemical compound O=CC(=O)C=O ICQNCHSXWNQIHC-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
• KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical group C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
• PRJHEJGMSOBHTO-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(3-hydroxypropyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 PRJHEJGMSOBHTO-UHFFFAOYSA-N 0.000 description 1
• 208000023769 AA amyloidosis Diseases 0.000 description 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 206010048998 Acute phase reaction Diseases 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• 241000531891 Alburnus alburnus Species 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 208000000103 Anorexia Nervosa Diseases 0.000 description 1
• YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• DGAKHGXRMXWHBX-ONEGZZNKSA-N Azoxymethane Chemical compound C\N=[N+](/C)[O-] DGAKHGXRMXWHBX-ONEGZZNKSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
• RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006242 Breast enlargement Diseases 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 206010007556 Cardiac failure acute Diseases 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 102000000989 Complement System Proteins Human genes 0.000 description 1
• 108010069112 Complement System Proteins Proteins 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
• 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 description 1
• 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
• 101100256026 Drosophila melanogaster meigo gene Proteins 0.000 description 1
• 208000030814 Eating disease Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 241000195955 Equisetum hyemale Species 0.000 description 1
• 241001539473 Euphoria Species 0.000 description 1
• 206010015535 Euphoric mood Diseases 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 101150019793 G2 gene Proteins 0.000 description 1
• 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
• 206010051635 Gastrointestinal tract adenoma Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 102000004263 Glutamate-Cysteine Ligase Human genes 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 101000866018 Homo sapiens DnaJ homolog subfamily B member 1 Proteins 0.000 description 1
• 101001138022 Homo sapiens La-related protein 1 Proteins 0.000 description 1
• 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 1
• 101000711237 Homo sapiens Serpin I2 Proteins 0.000 description 1
• 101000639792 Homo sapiens U2 small nuclear ribonucleoprotein A' Proteins 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 206010058490 Hyperoxia Diseases 0.000 description 1
• 201000002980 Hyperparathyroidism Diseases 0.000 description 1
• 206010060851 Hyperphosphatasaemia Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 206010065390 Inflammatory pain Diseases 0.000 description 1
• 102100023915 Insulin Human genes 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 208000008081 Intestinal Fistula Diseases 0.000 description 1
• 206010022699 Intestinal stenosis Diseases 0.000 description 1
• 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
• 101000913968 Ipomoea purpurea Chalcone synthase C Proteins 0.000 description 1
• 229930194542 Keto Natural products 0.000 description 1
• 206010023509 Kyphosis Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
• 229930064664 L-arginine Natural products 0.000 description 1
• 235000014852 L-arginine Nutrition 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 102100020859 La-related protein 1 Human genes 0.000 description 1
• 241000270457 Lacerta Species 0.000 description 1
• 239000005639 Lauric acid Substances 0.000 description 1
• 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010024715 Liver transplant rejection Diseases 0.000 description 1
• 101150069598 Lrrc7 gene Proteins 0.000 description 1
• 101150049547 Lyar gene Proteins 0.000 description 1
• 244000063103 Mangifera odorata Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
• 101100216020 Mus musculus Anpep gene Proteins 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 241000238367 Mya arenaria Species 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical class OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• 206010033307 Overweight Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 206010033647 Pancreatitis acute Diseases 0.000 description 1
• 241000282376 Panthera tigris Species 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 101000907988 Petunia hybrida Chalcone-flavanone isomerase C Proteins 0.000 description 1
• 208000034943 Primary Sjögren syndrome Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 206010038063 Rectal haemorrhage Diseases 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 206010062237 Renal impairment Diseases 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 102100034201 Sclerostin Human genes 0.000 description 1
• 206010039811 Secondary amyloidosis Diseases 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 102100034076 Serpin I2 Human genes 0.000 description 1
• 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
• 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
• 208000032023 Signs and Symptoms Diseases 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• 206010040844 Skin exfoliation Diseases 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 208000035286 Spontaneous Remission Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 101100494729 Syncephalastrum racemosum SPSR gene Proteins 0.000 description 1
• 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 241000718541 Tetragastris balsamifera Species 0.000 description 1
• 229940123464 Thiazolidinedione Drugs 0.000 description 1
• 206010043647 Thrombotic Stroke Diseases 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 101710182532 Toxin a Proteins 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 102100034465 U2 small nuclear ribonucleoprotein A' Human genes 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 208000027207 Whipple disease Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 210000001642 activated microglia Anatomy 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 231100000569 acute exposure Toxicity 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 208000005298 acute pain Diseases 0.000 description 1
• 201000003229 acute pancreatitis Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 210000005006 adaptive immune system Anatomy 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000011256 aggressive treatment Methods 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• 125000005103 alkyl silyl group Chemical group 0.000 description 1
• 125000005422 alkyl sulfonamido group Chemical group 0.000 description 1
• 125000001118 alkylidene group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 230000003872 anastomosis Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000003217 anti-cancerogenic effect Effects 0.000 description 1
• 230000003092 anti-cytokine Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 201000002064 aortic valve insufficiency Diseases 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 229940114078 arachidonate Drugs 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009697 arginine Nutrition 0.000 description 1
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
• 125000005129 aryl carbonyl group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• 230000010455 autoregulation Effects 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000008236 biological pathway Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000014461 bone development Effects 0.000 description 1
• 210000002665 bowman capsule Anatomy 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
• 229940026085 carbon dioxide / oxygen Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 238000013172 carotid endarterectomy Methods 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 210000001627 cerebral artery Anatomy 0.000 description 1
• 231100000481 chemical toxicant Toxicity 0.000 description 1
• 230000002113 chemopreventative effect Effects 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 239000012829 chemotherapy agent Substances 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000003759 clinical diagnosis Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 208000008609 collagenous colitis Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000002052 colonoscopy Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125758 compound 15 Drugs 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000008094 contradictory effect Effects 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 238000007269 dehydrobromination reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 235000005686 eating Nutrition 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 231100000284 endotoxic Toxicity 0.000 description 1
• 230000002346 endotoxic effect Effects 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 208000004267 erosive arthropathy Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 210000003499 exocrine gland Anatomy 0.000 description 1
• 229940014425 exodus Drugs 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 230000003890 fistula Effects 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 210000000285 follicular dendritic cell Anatomy 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 235000012055 fruits and vegetables Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
• 210000005095 gastrointestinal system Anatomy 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 230000004914 glial activation Effects 0.000 description 1
• 210000000585 glomerular basement membrane Anatomy 0.000 description 1
• 230000024924 glomerular filtration Effects 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 108091005995 glycated hemoglobin Proteins 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 244000005709 gut microbiome Species 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
• GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
• 210000001624 hip Anatomy 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• ZTUJDPKOHPKRMO-UHFFFAOYSA-N hydron;2,2,2-trifluoroethanamine;chloride Chemical compound Cl.NCC(F)(F)F ZTUJDPKOHPKRMO-UHFFFAOYSA-N 0.000 description 1
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
• 230000000222 hyperoxic effect Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
• 230000008076 immune mechanism Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000012442 inert solvent Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000003960 inflammatory cascade Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 210000004692 intercellular junction Anatomy 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 230000008991 intestinal motility Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 208000001286 intracranial vasospasm Diseases 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 230000037231 joint health Effects 0.000 description 1
• 208000018937 joint inflammation Diseases 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000008141 laxative Substances 0.000 description 1
• 230000002475 laxative effect Effects 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 229920006008 lipopolysaccharide Polymers 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000018191 liver inflammation Diseases 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 210000004705 lumbosacral region Anatomy 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 231100000682 maximum tolerated dose Toxicity 0.000 description 1
• 235000012054 meals Nutrition 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 229960004963 mesalazine Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 125000006384 methylpyridyl group Chemical group 0.000 description 1
• 244000005706 microflora Species 0.000 description 1
• 230000002025 microglial effect Effects 0.000 description 1
• 208000030247 mild fever Diseases 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004065 mitochondrial dysfunction Effects 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 210000003550 mucous cell Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 231100000707 mutagenic chemical Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 210000004479 myeloid suppressor cell Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 210000000282 nail Anatomy 0.000 description 1
• 208000026721 nail disease Diseases 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000009707 neogenesis Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 239000001272 nitrous oxide Substances 0.000 description 1
• 230000000422 nocturnal effect Effects 0.000 description 1
• ZBPYTVBKHKUNHG-UHFFFAOYSA-N non-3-enoic acid Chemical compound CCCCCC=CCC(O)=O ZBPYTVBKHKUNHG-UHFFFAOYSA-N 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 230000004768 organ dysfunction Effects 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000003431 oxalo group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000003950 pathogenic mechanism Effects 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 231100000857 poor renal function Toxicity 0.000 description 1
• 208000028173 post-traumatic stress disease Diseases 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 206010061928 radiculitis Diseases 0.000 description 1
• 238000002601 radiography Methods 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 102000037983 regulatory factors Human genes 0.000 description 1
• 108091008025 regulatory factors Proteins 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000008327 renal blood flow Effects 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 235000021264 seasoned food Nutrition 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 208000026425 severe pneumonia Diseases 0.000 description 1
• 210000002832 shoulder Anatomy 0.000 description 1
• 210000000323 shoulder joint Anatomy 0.000 description 1
• 238000002579 sigmoidoscopy Methods 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 231100000019 skin ulcer Toxicity 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 229960004274 stearic acid Drugs 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 210000005222 synovial tissue Anatomy 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960001367 tartaric acid Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960001712 testosterone propionate Drugs 0.000 description 1
• 229940124598 therapeutic candidate Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
• 125000003396 thiol group Chemical class [H]S* 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 230000006032 tissue transformation Effects 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 206010044008 tonsillitis Diseases 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 244000052613 viral pathogen Species 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1